donated posting 
Login Sitemap Search About us Contact Home
 
  Top News
Comparable Efficacy, Improved Safety and Lower Cost for High-Dose Bolus Dosing of AGGRASTAT® Compared to ReoPro® in STEMI Patients Undergoing Primary PCI: Three-Year Follow-Up for MULTISTRATEGY
Business Wire, 01.09.2010

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT® (tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro® (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.

more

Les primes restent «supportables»
La Tribune de Genève, 31.08.2010
more
  Next Event
Medical Devices Seminar 2010: Development, Manufacturing, Release
Zürich, 06.09.2010

The seminar offers an opportunity for industry to understand the basics, interpretation, application & being update with recent changes on the standards. The seminar will cover issues related to manufacturing of products, microbiological contamination of product, clinical trial & sterilization. more

Medical Manufacturing
Solothurn, 14.09.2010 - 15.09.2010
more
SimplyScience

CLS Communication language services

Impressum